Everything below concerns regulatory approval. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-26. Numbers and descriptions here follow the published literature rather than marketing material.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Linear tetrapeptide | Four residues joined by three peptide bonds |
| Sequence | Ala-Glu-Asp-Gly | Commonly abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free acid form |
| Monoisotopic mass | Approximately 390 Da | Matches values reported from mass spectrometry |
| Net charge near neutral pH | Negative | Contributed by glutamate and aspartate side chains |
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
The Ba'athist government of Syria ruled by the Al-Assad family was known for its extensive involvement in drug trade since the 1970s. As of 2022, the Syrian government financed the biggest multi-billion dollar drug trade in the world, mostly focused on an illegal drug known as Captagon, making it the world's largest narco-state. Its revenues from Captagon smuggling alone were estimated at $57 billion annually in 2022, which is approximately thrice the total trade of all Mexican cartels. General Maher al-Assad, younger brother of Syrian dictator Bashar al-Assad and commander of the Fourth Armoured Division, directly supervised the production, smuggling and profiteering of the drug business. Already suffering from severe financial problems as a result of corruption and civil war, profits from Captagon were said to be the "lifeline" of the Assad regime, through which it earned more than 90% of its total revenue. The smugglers receive direct training from the Syrian military to successfully conduct trafficking operations. Republican Guard, commanded by Maher al-Assad was one of the main Ba'athist military divisions that was engaged in perpetrating brutal crackdowns and mass violence against protestors across the country. In 2018, Bashar al-Assad assigned Maher as the commander of the 4th Armoured Division, a military unit that supervised the Assad regime's criminal enterprises like smuggling, drug trafficking, narcotics production and plunder of goods and resources.
== Protein structure == The monomer protein, consisting of 54 amino acid residues, is the smallest of the sweet proteins with a molecular weight of 6.5 kDa. The amino acid sequence of brazzein, adapted from the Swiss-Prot biological database of protein, is as follows: QDKCKKVYEN YPVSKCQLAN QCNYDCKLDK HARSGECFYD EKRNLQCICD YCEY The structure of brazzein was determined by proton nuclear magnetic resonance (NMR) at a pH of 5.2 and 22 °C. Brazzein has four evenly spaced disulfide bonds and no sulfhydryl groups. 3D analysis of brazzein showed one alpha-helix and three strands of anti-parallel beta sheet. This is not superficially similar to either of the other two sweet-tasting proteins, monellin and thaumatin. However, a recent 3D study shows that these three proteins possess similar "sweet fingers" believed to elicit the sweet taste. Residues 29–33 and 39–43, plus residue 36, as well as the C-terminus were found to be involved in the sweet taste of the protein. The charge of the protein also plays an important role in its interaction with the sweet taste receptor. Based on this knowledge a synthesised improved brazzein, called pGlu-1-brazzein, was reported to be twice as sweet as the natural counterpart.
PCP is well known for its primary action on the NMDA receptor, an ionotropic glutamate receptor. As such, PCP is a non-competitive NMDA receptor antagonist. The role of NMDAR antagonism in the effect of PCP, ketamine, and related dissociative agents was first published in the early 1980s by David Lodge and colleagues. Other NMDA receptor antagonists include ketamine, tiletamine, dextromethorphan, nitrous oxide, and dizocilpine (MK-801). Research also indicates that PCP inhibits nicotinic acetylcholine receptors (nAChRs) among other mechanisms. Analogues of PCP exhibit varying potency at nACh receptors and NMDA receptors. Findings demonstrate that presynaptic nAChRs and NMDA receptor interactions influence the postsynaptic maturation of glutamatergic synapses and consequently impact synaptic development and plasticity in the brain. These effects can lead to inhibition of excitatory glutamate activity in certain brain regions such as the hippocampus and cerebellum thus potentially leading to memory loss as one of the effects of prolonged use. Acute effects on the cerebellum manifest as changes in blood pressure, breathing rate, pulse rate, and loss of muscular coordination during intoxication. PCP, like ketamine, also acts as a potent dopamine D2High receptor partial agonist in rat brain homogenate and has affinity for the human cloned D2High receptor. This activity may be associated with some of the other more psychotic features of PCP intoxication, which is evidenced by the successful use of D2 receptor antagonists (such as haloperidol) in the treatment of PCP psychosis.
Sources: en.wikipedia.org
==== The Buddha's discovery of conditionality ==== Regarding the arising of suffering, SN 12.10 discusses how before the Buddha's awakening, he searched for the escape from suffering as follows: "when what exists is there old age and death? What is a condition for old age and death?", discovering the chain of conditions as expressed in the twelve nidanas and other lists. MN 26 also reports that after the Buddha's awakening, he considered that dependent origination was one of the two principles which were "profound (gambhira), difficult to see, difficult to understand, peaceful, sublime, beyond the scope of mere reasoning (atakkāvacara), subtle." The other principle which is profound and difficult to see is said to be Nirvana, "the stopping, or transcending, of conditioned co-arising" (Harvey). In the Mahānidānasutta (DN 15) the Buddha states that dependent origination is "deep and appears deep", and that it is "because of not understanding and not penetrating this teaching" that people become "tangled like a ball of string" in views (diṭṭhis), samsara, rebirth and suffering. SN 12.70 and its counterpart SA 347 state that "knowledge of Dhamma-stability" (dhamma-tthiti-ñānam) comes first, then comes knowledge of nirvana (nibbane-ñānam). However, while the process which leads to nirvāna is conditioned, nirvāna itself is called "unborn, unbecome, unmade, unconstructed" (Ud. 80–1). The Milinda Panha compares to how a mountain is not dependent on the path that leads to it (Miln. 269)". According to Harvey, since it is "not co-arisen (asamuppana) (It.
== Difference between channels and carriers == A carrier is not open simultaneously to both the extracellular and intracellular environments. Either its inner gate is closed, or its outer gate is closed. That is, its inner and outer gates are never open at the same time. In contrast, a channel can be open to both environments at the same time, allowing the molecules to diffuse without interruption. Carriers have binding sites, but pores and channels do not. When a channel is opened, millions of ions can pass through the membrane per second, but only 100 to 1000 molecules typically pass through a carrier molecule in the same time. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.
Membrane interaction of alpha-synuclein modulates or affects its rate of aggregation. The membrane-mediated modulation of aggregation is very similar to that observed for other amyloid proteins such as IAPP and abeta. Aggregated states of alpha-synuclein permeate the membrane of lipid vesicles. They are formed upon interaction with peroxidation-prone polyunsaturated fatty acids (PUFA) but not with monounsaturated fatty acids and the binding of lipid autoxidation-promoting transition metals such as iron or copper provokes oligomerization of alpha-synuclein. The aggregated alpha-synuclein has a specific activity for peroxidized lipids and induces lipid autoxidation in PUFA-rich membranes of both neurons and astrocytes, decreasing resistance to apoptosis. Lipid autoxidation is inhibited if the cells are pre-incubated with isotope-reinforced PUFAs (D-PUFA).
Sources: en.wikipedia.org
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.
The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.
The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.
Identity is normally confirmed by mass spectrometry, which checks the measured mass against the expected value near 390 daltons. Reverse-phase high-performance liquid chromatography is used alongside it to assess purity. Amino acid analysis can provide additional composition data.